AGM
EWTX icon

Alpine Global Management’s Edgewise Therapeutics EWTX Stock Holding History

Alpine Global Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,908
Closed -$250K – 252
2024
Q2 		$250K Buy
+13,908
New +$243K 0.04% 271

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alpine Global Management's EWTX Position: Q3 2024 in Review

Alpine Global Management sold out of Edgewise Therapeutics (EWTX) in Q3 2024, closing a stake of 13,908 shares — an estimated $250K sold.

Alpine Global Management first reported a position in EWTX in Q2 2024 and held it in 1 quarter. The position peaked at $250K in Q2 2024. 177 funds tracked by Wall St. Rank hold EWTX as of Q3 2024.

  • Alpine Global Management reported no remaining Edgewise Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 13,908 Edgewise Therapeutics shares in Q3 2024, an estimated $250K.
  • Alpine Global Management first reported a position in Edgewise Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Edgewise Therapeutics position peaked at $250K in Q2 2024.
  • 177 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.